TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04147988

Intervention type: OTHER
Group type: OTHER
Intervention: screening and diagnostic assessment DONALD T unit list
Description: Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
Study: NCT04399876

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate
Study: NCT03488121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poster
Description: Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thank-you Letter
Description: Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thank-you Letter
Description: Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
Study: NCT00330863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone microspheres
Description: Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Target dose is 4 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Target dose is 15 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Target dose is 600 mg/day.
Study: NCT01473121

Intervention type: OTHER
Intervention: No Intervention
Description: All treatment options (inc. surgery, TACE, drugs) will be registered.
Study: NCT00330863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Target dose is 120 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Target dose is 20 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Target dose is 6 mg/day.
Study: NCT00999219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK199B
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK199B
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: oral
Study: NCT00635830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
Study: NCT02692729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transverse supraumbilical
Description: transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pfannenstiel incision
Description: Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
Study: NCT01106521

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Permanent breast seeds implant
Description: Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
Study: NCT01425476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study: NCT00999219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: oral
Study: NCT01362218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
Description: A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin, ramipril, acetylsalicylic acid
Description: A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
Study: NCT03196193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation
Description: Fractured bone fragments are reduced and stabilized by intramedullary nail.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Fractured bone fragments are reduced and stabilized by intramedullary nail.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZNN CM Asia
Description: Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZNN CM Asia
Description: Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Support Screw
Description: Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
Study: NCT04959253

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Psilocybin assisted therapy
Description: A package of psychological therapy and a single dosing session of psilocybin.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assisted therapy
Description: A package of psychological therapy and a single dosing session of placebo.
Study: NCT05353101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% eye drops
Description: Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%
Description: Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
Study: NCT05014048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 20 mikrog vitamin D3 daily
Study: NCT01665092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Carnitine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Carnitine
Study: NCT01425476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
Study: NCT01665092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Carnitine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00653276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Description: ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: cyclosporine
Description: single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: cyclosporine
Description: single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
Study: NCT02390544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
Study: NCT04152421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software use
Description: The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities.
Study: NCT03147391

Intervention type: DEVICE
Intervention: LAA closure with LAmbre
Description: Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
Study: NCT01537419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy
Description: Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Enhanced Non-directive Supportive Therapy
Description: Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
Study: NCT02700958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM Remote ischemic preconditioning
Description: SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
Study: NCT05014048

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03831802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace with Alert and Mate apps
Description: Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embrace with Mate app only
Description: Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
Study: NCT04496362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous heparin anticoagulation
Description: The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.
Study: NCT02836834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001
Description: Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
Study: NCT01453413

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Glucose meter
Description: Staff tested subject Blood Glucose using a Blood Glucose meter.
Study: NCT01189526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macular laser photocoagulation
Description: Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
Study: NCT03898674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra venous fluid
Description: Volume of intra venous fluid administered during GDT protocol
Study: NCT03896464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft tissue hamstring autograft
Description: Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps tendon autograft
Description: Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
Study: NCT00910767

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional insulin pump delivery
Description: Subcutaneous delivery of Novorapid insulin according to usual pump regime

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop
Description: Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
Study: NCT04191798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation using the KinexConnect system for rehabilitation after TKA.
Description: KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional outpatient PT for rehabilitation after TKA.
Description: Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
Study: NCT00949611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRAX + Decision Aid
Description: Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRAX estimated fracture risk
Description: The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
Study: NCT01222910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride
Study: NCT02325063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP-L Injection
Description: Patients will be treated with an injection of leukocyte and platelet rich plasma.
Study: NCT01484184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPINALON (buspirone + levodopa + cardidopa)
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPINALON (buspirone + levodopa + cardidopa)
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
Study: NCT04075019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Raising Healthy Children intervention, including teacher training, child skill development, and parent training
Study: NCT02325063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Patients will be treated with an injection of Type A Botulinum toxin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoid injection
Description: Patients will be treated with an injection of Corticoids.
Study: NCT03615417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Description: Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard anesthesia FaceMask (FM)
Description: Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated.
Study: NCT02519517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia
Description: During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
Study: NCT04562259

Intervention type: RADIATION
Intervention: Verification of Kimmerle's anomaly by x-ray methods of research
Description: In patients with Kimmerle's anomaly, using computed tomography of the brain with the capture of the upper cervical spine and cervical spine, it is planned to determine at what age this pathology is more common, localization of the anomaly (right, left), complete or incomplete form of the anomaly.